BDNF raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-20 and is reviewed periodically as new material appears.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.
Solubility behavior is a practical concern for handling. Selank dissolves readily in water and in common aqueous buffers, which simplifies preparation of working solutions. The choice of solvent, ionic strength, and pH can influence aggregation over time, particularly at higher concentrations. Aqueous solutions are typically sterile-filtered before use. Because stability depends on several variables, storage and handling notes should be treated as general guidance rather than fixed rules, and specific values are best confirmed against a certificate of analysis for each batch.
| Property | Value | Notes |
|---|---|---|
| Principal proposed target | GABA-A receptor complex | Hypothesis derived mainly from animal pharmacology |
| Common behavioral assay | Elevated plus maze | Rodent test for anxiety-like behavior |
| Reported molecular marker | Hippocampal BDNF expression | Measured by immunoassay or mRNA quantification |
| Typical dosing route | Intranasal | Chosen to reduce first-pass metabolism |
| Reported plasma half-life | Minutes | Based on limited peptide stability data |
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
=== Regulation of living organisms === With acceptance of premarket notification 510(k) k033391 in January 2004, the FDA granted Ronald Sherman permission to produce and market medical maggots for use in humans or other animals as a prescription medical device. Medical maggots represent the first living organism allowed by the Food and Drug Administration for production and marketing as a prescription medical device. In June 2004, the FDA cleared Hirudo medicinalis (medicinal leeches) as the second living organism legal to use as a medical device. The FDA also requires that milk be pasteurized to remove bacteria.
The BioBricks assembly standard was described and introduced by Tom Knight in 2003 and it has been constantly updated since then. Currently, the most commonly used BioBricks standard is the assembly standard 10, or BBF RFC 10. BioBricks defines the prefix and suffix sequences required for a DNA part to be compatible with the BioBricks assembly method, allowing the joining of all DNA parts which are in the BioBricks format. The prefix contains the restriction sites for EcoRI, NotI and XBaI, while the suffix contains the SpeI, NotI and PstI restriction sites. Outside of the prefix and suffix regions, the DNA part must not contain these restriction sites. To join two BioBrick parts together, one of the plasmids is digested with EcoRI and SpeI while the second plasmid is digested with EcoRI and XbaI. The two EcoRI overhangs are complementary and will thus anneal together, while SpeI and XbaI also produce complementary overhangs which can also be ligated together. As the resulting plasmid contains the original prefix and suffix sequences, it can be used to join with more BioBricks parts. Because of this property, the BioBricks assembly standard is said to be idempotent in nature. However, there will also be a "scar" sequence (either TACTAG or TACTAGAG) formed between the two fused BioBricks.
Different bat species have different diets, including insects, nectar, pollen, fruit and even vertebrates. Megabats are mostly fruit, nectar and pollen eaters. Due to their small size, high metabolism and rapid burning of energy through flight, bats must consume large amounts of food for their size. Insectivorous bats may eat over 120 percent of their body weight per day, while frugivorous bats may eat over twice their weight. They can travel significant distances each night, exceptionally as much as 38.5 km (24 mi) in the spotted bat (Euderma maculatum), in search of food. Bats may acquire water from the food they eat or drink from sources like lakes and streams, flying over the surface and dipping their tongues into the water. Bats as a group appear to be losing vitamin C synthesis. Such a loss was recorded in 34 bat species from six major families, both insect- and fruit-eating, with the cause being a single mutation inherited from a common ancestor. Vitamin C synthesis has been recorded in at least two species of bat, Leschenault's rousette (Rousettus leschenaultii) and the great roundleaf bat (Hipposideros armiger).
The medio-lateral incision is made between the vagina at an angle and is not as likely to tear through to the anus. The medio-lateral cut takes more time to heal than the median cut. Vaginectomy is surgery to remove all or part of the vagina, and is usually used to treat malignancy. Removal of some or all of the sexual organs can result in damage to the nerves and leave behind scarring or adhesions. Sexual function may also be impaired as a result, as in the case of some cervical cancer surgeries. These surgeries can impact pain, elasticity, vaginal lubrication and sexual arousal. This often resolves after one year but may take longer. Women, especially those who are older and have had multiple births, may choose to surgically correct vaginal laxity. This surgery has been described as vaginal tightening or rejuvenation. While a woman may experience an improvement in self-image and sexual pleasure by undergoing vaginal tightening or rejuvenation, there are risks associated with the procedures, including infection, narrowing of the vaginal opening, insufficient tightening, decreased sexual function (such as pain during sexual intercourse), and rectovaginal fistula. Women who undergo this procedure may unknowingly have a medical issue, such as a prolapse, and an attempt to correct this is also made during the surgery. Surgery on the vagina can be elective or cosmetic. Women who seek cosmetic surgery can have congenital conditions, physical discomfort or wish to alter the appearance of their genitals.
Sources: en.wikipedia.org
=== Veterinary care === In the United States, more than 15,000 domesticated animals are bitten by snakes each year. Rattlesnake envenomations account for 80% of the deadly incidents. Dogs are most commonly bitten on the front legs and head. Horses generally receive bites on the muzzle, and cattle on their tongues and muzzles. If a domesticated animal is bitten, the hair around the bite should be removed so the wound can be clearly seen. The crotaline Fab antivenom has been shown to be effective in the treatment of canine rattlesnake bites. Symptoms include swelling, slight bleeding, sensitivity, shaking, and anxiety.
==== Road to war ==== Liu Wenhui's 1990 biography asserts that conflict between the two Lius was almost inevitable. Due to the consolidation of power in Sichuan that had occurred over the 1920s, Liu Wenhui and Liu Xiang had become the two most powerful warlords in the province. Liu Wenhui's assumption of the governorship in 1929 had turned many smaller warlords against him. By controlling the lower reaches of the Yangtze and the Qutang Gorge, Liu Xiang held the geographic advantage over his uncle, having priority in purchasing weapons from abroad (which entered Sichuan through the Yangtze), and had built a navy of three gunboats by fitting merchant ships with iron hulls. This also meant that Liu Xiang could block weapons from reaching Liu Wenhui's upstream domains, an ability that he would use to his advantage. Liu Xiang was also reportedly under the sway of his Taoist mystic advisor, Liu Congyun, who had told him that he was destined to unite the province under his rule. Yet another supposed factor contributing to conflict was the interference of Chiang Kai-shek, who did not want either warlord to become too powerful. Most sources agree that Liu Wenhui's abortive attempt to acquire military aviation assets in 1931 was the spark that led him to conflict with his nephew. Official Chinese sources state that a shipment ordered by Liu of foreign aircraft components worth 2 million yuan was seized by Liu Xiang at the port of Wanxian in Chongqing, leading to heightened tensions between the two Lius.
=== Cross-linking micelles === Polymer-based micelles that undergo crosslinking reactions can induce the formation of nanogels. Crosslinking either the core or the shell of a preexisting micelles can synthesize nanogels with a "high degree of spatial organization".
=== General === The croaking gourami is a fairly shy, peaceful fish that does well in most community aquaria, not causing problems with tankmates. Males can be fairly territorial and aggressive towards each other during breeding periods, but will not cause harm and can peacefully coexist given a large enough aquarium. This species requires a tank no smaller than 40 L (11 U.S. gal), preferably larger. The croaking gourami will prowl about all areas of the aquarium, preferring to lurk among reeds and under large leaves close to the water surface. At night, they might be found "sleeping" at the bottom, even resting on the substrate (which is not normally a cause for concern), or hovering motionless at the water surface. Like all members of the suborder Anabantoidei, if necessary, the croaking gourami can breathe atmospheric oxygen from above the water surface using a specialized labyrinth organ. It is important, therefore, that the surface of the water be exposed to fresh air, usually accomplished by keeping them in an open-top tank or using a hood that allows air ventilation. If the tank has good air pumps, this is not always needed, since the air pumps will refresh the air above the water. The aquarium should be heavily planted and have at least part of the surface shaded by broad leaves or floating plants, since the croaking gourami will become severely stressed in bare tanks without various hiding places. A darker substrate will make this fish feel comfortable and help show off its subtle colors.
The UK government is to examine the potential purchase of The Daily Telegraph by a consortium backed by Sheikh Mansour bin Zayed Al Nahyan. The coldest night in the UK since mid-March is recorded, with temperatures dipping to as low as −9.4 °C (15.1 °F) in Cumbria. Weather warnings remain in place for many regions.
Sources: en.wikipedia.org
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.
Behavioral endpoints include time spent in open arms of the elevated plus maze and avoidance latencies. Biochemical endpoints include BDNF concentration, cytokine levels, and monoamine metabolite ratios in brain tissue.
Most published studies are small, originate from a limited number of laboratories, and lack independent replication. Dose-response relationships, measured brain exposure, and long-term outcomes are not well characterized.
Reverse-phase HPLC is the usual method and gives a percentage purity value. Mass spectrometry then confirms the molecular mass. Together they provide a basic identity and purity profile for a lot.